The trial is a phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5. Recently, the company ...

Opus Genetics has dosed the first subject in its Phase I/II clinical trial of OPGx-Best1 gene therapy for the treatment of ...

Emerging gene therapy administered through a one-time subretinal injection marks a major milestone for the inherited retinal disease ...

Inherited retinal dystrophy (IRD) isn’t one disease. It’s many different ones that cause your retina to break down and stop working. They can make you color-blind or night blind. Others can lead to ...

Please provide your email address to receive an email when new articles are posted on . The loss of UBAP1L gene function appears to be associated with nonsyndromic retinal dystrophy, according to ...

ANN ARBOR, Mich.--(BUSINESS WIRE)--OcuSciences, Inc., a medical device company developing retinal imagers to detect early disease by assessing retinal metabolic activity, today announced the ...

When I found out I have retinitis pigmentosa (RP), a type of inherited retinal dystrophy, I was shocked. Nobody in my family has vision problems. I had some trouble with my vision, but I thought it ...

MeiraGTx Holdings plc announced promising results from a first-in-human study published in The Lancet, involving a gene therapy treatment for children with AIPL1-associated retinal dystrophy, ...

(RTTNews) - MeiraGTx Holdings Plc. (MGTX), a clinical-stage genetic medicines company, on Friday announced the progress in its gene therapy program for Leber Congenital Amaurosis 4 or LCA4, a severe ...

Please provide your email address to receive an email when new articles are posted on . The Foundation Fighting Blindness and the Nixon Visions Foundation are working together to launch the Nixon ...

Researchers report that deleting one of the inhibitors of the RPE65 gene in a mouse model that carries a human disease mutation prevents degeneration of cone photoreceptors that are used for daytime ...

Opus Genetics (IRD) announced that the first participant has been dosed in the Company’s OPGx-BEST1 Phase 1/2 clinical trial for Best disease. Best disease, or vitelliform macular dystrophy, is a rare ...